Innovent to seek China approval of high-dose obesity shot after Phase 3 hit
信达生物拟在三期成功后寻求manbetx3.0 批准其高剂量减重注射剂

A high-dose version of Innovent Biologics’ obesity drug led to patients with moderate-to-severe disease losing 18.6% of their body weight in about a year and two months, according to data from a late-stage China-based trial.
一项在manbetx3.0 开展的晚期临床试验数据显示，接受高剂量版本的信达生物减重药物治疗的中重度患者在约14个月内平均减重18.6%。